Amgen Inc. (AMGN) dividends
AMGN on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
Amgen Inc. dividend: key facts
Own Amgen Inc.? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next AMGN dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
| Ex-dividend | Payment | Per share | Currency | Type |
|---|---|---|---|---|
| 20 Nov 2026 Declared | Pays 11 Dec 2026 | $2.52 | USD | Quarterly |
| 21 Aug 2026 | Paid 11 Sep 2026 | $2.52 | USD | Quarterly |
| 15 May 2026 | Paid 5 Jun 2026 | $2.52 | USD | Quarterly |
| 13 Feb 2026 | Paid 6 Mar 2026 | $2.52 | USD | Quarterly |
| 21 Nov 2025 | Paid 12 Dec 2025 | $2.38 | USD | Quarterly |
| 22 Aug 2025 | Paid 12 Sep 2025 | $2.38 | USD | Quarterly |
| 16 May 2025 | Paid 6 Jun 2025 | $2.38 | USD | Quarterly |
| 14 Feb 2025 | Paid 7 Mar 2025 | $2.38 | USD | Quarterly |
| 18 Nov 2024 | Paid 9 Dec 2024 | $2.25 | USD | Quarterly |
| 16 Aug 2024 | Paid 6 Sep 2024 | $2.25 | USD | Quarterly |
| 16 May 2024 | Paid 7 Jun 2024 | $2.25 | USD | Quarterly |
| 15 Feb 2024 | Paid 7 Mar 2024 | $2.25 | USD | Quarterly |
| 16 Nov 2023 | Paid 8 Dec 2023 | $2.13 | USD | Quarterly |
| 17 Aug 2023 | Paid 8 Sep 2023 | $2.13 | USD | Quarterly |
| 17 May 2023 | Paid 8 Jun 2023 | $2.13 | USD | Quarterly |
| 14 Feb 2023 | Paid 8 Mar 2023 | $2.13 | USD | Quarterly |
| 16 Nov 2022 | Paid 8 Dec 2022 | $1.94 | USD | Quarterly |
| 17 Aug 2022 | Paid 8 Sep 2022 | $1.94 | USD | Quarterly |
| 16 May 2022 | Paid 8 Jun 2022 | $1.94 | USD | Quarterly |
| 14 Feb 2022 | Paid 8 Mar 2022 | $1.94 | USD | Quarterly |
| 15 Nov 2021 | Paid 8 Dec 2021 | $1.76 | USD | Quarterly |
| 16 Aug 2021 | Paid 8 Sep 2021 | $1.76 | USD | Quarterly |
| 14 May 2021 | Paid 8 Jun 2021 | $1.76 | USD | Quarterly |
| 11 Feb 2021 | Paid 8 Mar 2021 | $1.76 | USD | Quarterly |
Five-year outlook
Estimates, not forecasts of what will be paid: dividends can be cut at any time.
| Period | Per share | Currency | Yield at today's price | Confidence |
|---|---|---|---|---|
| Next 12 months | $10.6131 | USD | 2.39% | High |
| Year 2 | $11.3614 | USD | 2.56% | Medium |
| Year 3 | $12.1626 | USD | 2.74% | Medium |
| Year 4 | $13.0202 | USD | 2.93% | Low |
| Year 5 | $13.9382 | USD | 3.14% | Low |
How we got these figures. Raised 13 years in a row; grown at 7.1% a year (its recent pace).
With no growth at all, each year would be $10.08.
Reported financials
Annual figures from filings, converted to units.
| Year to | Revenue | Net income | EPS | Free cash flow | Source |
|---|---|---|---|---|---|
| 31 Dec 2025US-GAAP USD | $36.75bn | $7.71bn | $14.23 | $8.10bnDerived | Source (opens in a new tab) |
| 31 Dec 2024US-GAAP USD | $33.42bn | $4.09bn | $7.56 | $10.39bnDerived | Source (opens in a new tab) |
| 31 Dec 2023US-GAAP USD | $28.19bn | $6.72bn | $12.49 | $7.36bnDerived | Source (opens in a new tab) |
| 31 Dec 2022US-GAAP USD | $26.32bn | $6.55bn | $12.11 | $8.78bnDerived | Source (opens in a new tab) |
| 31 Dec 2021US-GAAP USD | $25.98bn | $5.89bn | $10.28 | $8.38bnDerived | Source (opens in a new tab) |
| 31 Dec 2020US-GAAP USD | $25.42bn | $7.26bn | $12.31 | $9.89bnDerived | Source (opens in a new tab) |
About Amgen Inc.
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
From Wikipedia, CC BY-SA 4.0.
Next 12 months
| 20 Nov 2026Ex-dividend | USD | $2.52Declared |
| 13 Feb 2027Ex-dividend | USD | $2.6977Estimate |
| 15 May 2027Ex-dividend | USD | $2.6977Estimate |
| 21 Aug 2027Ex-dividend | USD | $2.6977Estimate |
Estimate confidence: High
Financial health
A summary of the scores below, each 0 to 100. Based on the year to 31 Dec 2025.
Company news
- Amgen price target raised to $515 from $460 at Argus12 Nov 2026 · TheFly
Argus raised the firmâs price target on Amgen (AMGN) to $515 from $460 and keeps a Buy rating on the shares. The company has a strong pipeline of potential newâ¦
- Amgen reports results from Phase 3 OASIZ-301 study of dazodalibep11 Nov 2026 · TheFly
Amgen (AMGN) announced results from the Phase 3 OASIZ-301 study of dazodalibep, the only global Phase 3 trial to demonstrate clinically meaningful improvements in systemic disease activity and symptom...
- Amgen's experimental Sjogren's drug meets late-stage trial goal11 Nov 2026 · Reuters
Amgen said on âWednesday its âexperimental âdrug showed â sustained âreduction in âdisease activity in âa âlate-stage study âof â patients with Sjogren's âdisease, âan â autoimmune condition.
- AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÃGREN'S DISEASE11 Nov 2026 · PRNewsWire
Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/ -...
- Amgenâs Repatha shows cost-effectiveness in cardiovascular study10 Nov 2026 · TheFly
Amgen (AMGN) announced new data at the American Heart Association Scientific Sessions 2026 that further strengthen the case for more intensive lowering of low-density lipoprotein cholesterol, or LDL-C...
- NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM10 Nov 2026 · PRNewsWire
Independent VESALIUS-CV Analysis Finds Repatha Highly Cost-Effective in High-Risk Patients Without a Prior Heart Attack or Stroke Long-Term FOURIER External-Control Analysis Shows Repatha Associated W...
- Amgen downgraded to Hold from Buy at Freedom Broker6 Nov 2026 · TheFly
Freedom Broker downgraded Amgen (AMGN) to Hold from Buy with a price target of $470, up from $450. The firm views the companyâs Q3 report as strong. Freedom cites valuationâ¦
- Amgenâs Repatha lowers heart attack risk 20% vs. ezetimibe in real-world study5 Nov 2026 · TheFly
Amgen (AMGN) announced results from a large real-world study showing that treatment with Repatha â evolocumab â reduced the risk of fatal or nonfatal heart attacks by 20% compared withâ¦
Dividend data and price last updated 18 Nov 2026.